We remain on track to finish dosing of all subjects by the end of second quarter 2018," stated Andrew Rae, chief executive officer of iCo Therapeutics.
"Full analysis of study data is expected shortly afterwards in third quarter 2018."
"these posts are not of a licensed investment advisor or analyst nor does he give out buy, sell or hold advice to anyone"
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.